晚期霍奇金淋巴瘤ABVD后完全代谢缓解者大肿块放疗的III期随机试验最终结果
样本量不足以检测≤10%的获益。
要点
- 晚期霍奇金淋巴瘤ABVD后CMR且基线大肿块者,放疗未显著改善2年EFS。
- OBS组2年EFS达85.8%,提示该人群观察结局良好。
- 样本量不足,不能排除放疗≤10%的较小获益。
核心结论
- 在晚期霍奇金淋巴瘤ABVD化疗后达CMR且基线有大肿块的患者中,巩固放疗未显著改善2年EFS,主要终点未达到。
- 样本量不足以检测≤10%的EFS获益,放疗在该 setting 中可能更有限的作用仍待明确。
研究设计与样本
- III期随机对照试验(Fondazione Italiana Linfomi HD0801),纳入基线大肿块(最大径≥5 cm)且2和6周期ABVD后达CMR的晚期霍奇金淋巴瘤患者。
- 样本量按RT组EFS提高20%(从60%至80%)估算。
主要发现
- 随机至OBS的CMR患者结局良好。
关键数值与推荐
- 大肿块定义:基线最大直径≥5 cm。
- CMR定义:2和6周期ABVD后达完全代谢缓解。
临床怎么用
- 对于晚期霍奇金淋巴瘤ABVD后达CMR且基线有大肿块的患者,可考虑观察而非常规巩固放疗。
- 放疗的潜在获益可能有限,决策需个体化并结合患者风险。
局限性
- 样本量不足以检测≤10%的EFS获益。
- 主要终点未达到,但研究未完全排除放疗的较小作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of consolidation radiotherapy (RT) for bulky lesions is controversial in patients with advanced-stage Hodgkin lymphoma who achieve complete metabolic response (CMR) after doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD)-based chemotherapy. We present the final results of the Fondazione Italiana Linfomi HD0801 trial, which investigated the potential benefit of RT in that setting. In this phase 3 randomized study, patients with a bulky lesion at baseline (a mass with largest diameter ≥5 cm) who have CMR after 2 and 6 ABVD cycles were randomly assigned 1:1 to RT vs observation (OBS) with a primary endpoint of event-free survival (EFS) at 2 years. The sample size was calculated estimating an EFS improvement for RT of 20% (from 60% to 80%). The secondary end point was progression-free survival (PFS). One hundred sixteen patients met the inclusion criteria and were randomly assigned to RT or OBS. Intention-to-treat (ITT) analysis showed a 2-year EFS of 87.8% vs 85.8% for RT vs OBS (hazard ratio [HR], 1.5; 95% confidence interval [CI], 0.6-3.5; P = .34). At 2 years, ITT-PFS was 91.3% vs 85.8% (HR, 1.2; 95% CI, 0.5-3; P = .7). Patients in CMR randomly assigned to OBS had a good outcome, and the primary end point of a 20% benefit in EFS for RT was not met. However, the sample size was underpowered to detect a benefit of 10% or less, keeping open the question of a potential, more limited role of RT in this setting. This trial was registered at www.clinicaltrials.gov as #NCT00784537.
引用
- Ricardi U, Levis M, Evangelista A, et al. Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Adv. 2021. PMID: 34597375. doi:10.1182/bloodadvances.2021005150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。